National Eye Institute; Notice of Closed Meetings, 9166 [2024-02653]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
9166
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Todd Everett White, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–3962, todd.white@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Program
Project: Neuroscience and Substance use.
Date: March 12, 2024.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Anne-Sophie Marie Lucie
Wattiez, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 594–4642, annesophie.wattiez@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Bioengineering, Surgery,
Anesthesiology, and Trauma.
Date: March 13, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Donald Scott Wright,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
MSC 7854, Bethesda, MD 20892, (301) 435–
8363, wrightds@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Epidemiology and Population
Sciences.
Date: March 13–14, 2024.
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rebecca I. Tinker, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, (301) 435–0637, tinkerri@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 6, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02696 Filed 2–8–24; 8:45 am]
17:20 Feb 08, 2024
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Substance Abuse and Mental Health
Services Administration
National Eye Institute; Notice of Closed
Meetings
Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel; BRAIN Initiative:
New Concepts and Early-Stage Research for
Recording and Modulation in the Nervous
System (R21).
Date: March 19, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700
Rockledge Dr., Bethesda, MD 20817.
Contact Person: Brian Hoshaw, Ph.D.,
Designated Federal Official, Division of
Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Dr., Rockville, MD 20892, 301–
451–2020, hoshawb@mail.nih.gov.
Name of Committee: National Eye Institute
Special Emphasis Panel; Conference Grant
Applications (R13).
Date: April 15, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 6700
Rockledge Dr., Bethesda, MD 20817.
Contact Person: Jeanette M. Hosseini,
Ph.D., Scientific Review Officer, Division of
Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B
Rockledge Drive, Bethesda, MD 20892, 301–
451–2020, jeanetteh@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.867, Vision Research,
National Institutes of Health, HHS)
Dated: February 5, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02653 Filed 2–8–24; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
VerDate Sep<11>2014
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jkt 262001
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention’s
(CSAP) Drug Testing Advisory Board
(DTAB) will convene via web
conference on March 5, 2024, from 10
a.m. EST to 12:45 p.m. EST.
The board will meet in open-session
March 5, 2024, from 10 a.m. EST to
12:45 p.m. EST to hear presentations
regarding proposed changes to the
analyte table including fentanyl
prevalence, fentanyl immunoassay
updates, cost and benefits analysis and
a summary of public comments received
regarding the proposed changes to the
HHS Drug Testing Panels.
Section 8105 of the Fighting Opioid
Abuse in Transportation Act, included
in the SUPPORT for Patients and
Communities Act, required the
Secretary to determine whether it is
justified, based on the reliability and
cost-effectiveness of testing, to revise
the Mandatory Guidelines for Federal
Workplace Drug Testing Programs to
include fentanyl. Section 8105
additionally required the Secretary to
consider whether to include any other
drugs or other substances listed in
Schedule I and II of Controlled
Substances Act (CSA). Norfentanyl is a
metabolite of fentanyl. Because it is also
an immediate precursor used in the
illicit manufacture of fentanyl, it is a
Schedule II substance under the CSA.
Fentanyl is involved in a large
proportion of overdose deaths in the
United States and is therefore an
important public safety concern.
Furthermore, fentanyl is increasingly
used as a stand-alone substance, not in
conjunction with heroin and other
substances. According to the National
Forensic Laboratory Information System
(NFLIS) 2022 report, fentanyl was the
3rd most frequently identified drug and
accounted for 13.81% of all drugs
reported by forensic laboratories.1
Norfentanyl is an important component
of identifying people who use fentanyl
when urine is the specimen matrix.
Fentanyl has been detected in oral fluid
in patients receiving pain management
1 National Forensic Laboratory Information
System (NFLIS). (2022). NFLIS-Drug 2022 Annual
Report. U.S. Department of Justice, Drug
Enforcement Agency, Diversion Control Division.
2022 NFLIS-Drug Annual Report.pdf.
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 89, Number 28 (Friday, February 9, 2024)]
[Notices]
[Page 9166]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02653]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Eye Institute Special Emphasis
Panel; BRAIN Initiative: New Concepts and Early-Stage Research for
Recording and Modulation in the Nervous System (R21).
Date: March 19, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Eye Institute, 6700 Rockledge Dr., Bethesda, MD
20817.
Contact Person: Brian Hoshaw, Ph.D., Designated Federal
Official, Division of Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B Rockledge Dr., Rockville, MD
20892, 301-451-2020, [email protected].
Name of Committee: National Eye Institute Special Emphasis
Panel; Conference Grant Applications (R13).
Date: April 15, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Eye Institute, 6700 Rockledge Dr., Bethesda, MD
20817.
Contact Person: Jeanette M. Hosseini, Ph.D., Scientific Review
Officer, Division of Extramural Research, National Eye Institute,
National Institutes of Health, 6700 B Rockledge Drive, Bethesda, MD
20892, 301-451-2020, [email protected].
(Catalogue of Federal Domestic Assistance Program No. 93.867, Vision
Research, National Institutes of Health, HHS)
Dated: February 5, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-02653 Filed 2-8-24; 8:45 am]
BILLING CODE 4140-01-P
